1h Free Analyst Time
This report offers market size & forecast data for the global erectile dysfunction treatment market. The revenue generated from the sale of drugs & devices is included in the report. This report provides a comprehensive and current market scenario of the global erectile dysfunction treatment market, including the global erectile dysfunction treatment market size, anticipated market forecast, relevant market segmentations, and industry trends.Speak directly to the analyst to clarify any post sales queries you may have.
The study considers a detailed scenario of the present global erectile dysfunction treatment market and its market dynamics for 2024-2029. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent players operating in the market.
KEY HIGHLIGHTS
- The global erectile dysfunction treatment market was valued at $4,727.51 million in 2023 and registered a negative CAGR of -0.94%. The market reach is mainly attributed to the rising prevalence of erectile dysfunction and associated chronic diseases such as diabetes, benign prostate hyperplasia, prostate cancer, and CVDs, which can, in turn, pose high-risk factors for the occurrence of disease, are critical factors for the erectile dysfunction treatment market.
- In 2023, North America and Europe dominated the market with a market share of 33.63% and 29.05%, respectively. APAC is expected to be the fastest-growing market for erectile dysfunction treatment in terms of revenue during the forecast period, with a CAGR of 2.70%.
- Based on product, the drugs segment dominated the market over the devices segment and accounted for a market share of 79.08%, whereas the devices segment accounted for a 20.92% share. However, during the forecast period, the devices segment will likely witness the highest incremental and absolute growth of $252.58 million and 25.54%, respectively.
- The route of administration (RoA) segment of ED drugs is sub-segmented into oral medications, penile injections, and topical drugs. Among the three sub-segments, oral drugs occupied the largest share, which is attributed to the high adoption of branded drugs. Overall, 92.57% was occupied by oral drugs, followed by penile injections at 4.70% and topical drugs at 2.73%.
- Rising awareness, growing patient willingness to demand medical assistance for disease care and management, and the increasing presence of favorable guidelines that recommend the use of drugs and devices for the treatment of ED are expected to propel the market growth during the forecast period.
- Bayer, Pfizer, Eli Lilly and Company, Coloplast, and Boston Scientific are some of the leading players currently dominating the global erectile dysfunction treatment market. The major players focus on strategic acquisitions and collaborations with emerging players to enter the ED treatment market and gain access to commercially launched products.
VENDORS LIST
- Bayer
- Pfizer
- Coloplast
- Eli Lilly and Company
- Boston Scientific
- Teva Pharma
- Viatris
- Dong-A Socio
- Vivus
- Cristalia
- Dr.Reddy’s
- Aurobindo
- Seelos Therapeutics
- Menarini Group
- GSK plc
- Futura Medical
- Sanofi
- Cipla
- Lupin
- Advanz Pharma
- Sandoz
- IX Biopharma
- Domier Medtech
- Zephyr Surgical Implants
- Augusta Medical Systems
- Metuchen Pharmaceuticals
- SK Chemicals
- Endo International
- Ferring Pharmaceuticals
- Alembic Pharmaceuticals
- Guangzhou Pharmaceuticals
- Launch Medical
- Bonro Medical
- Owen Mumford
- Direx Group
- Zimmer Medizin Systems
- MTS Medical UG
- Medispec
- Inceler Medical
- NOVAmedtek
- Wikkon
- Top Quality Group
- Promedon
- Timm Medical Technologies
- Global Life Technologies
- Urology Health Store
- Hims
REPORT HIGHLIGHTS
PRODUCT SEGMENTATION & FORECAST
- Product type
- Drugs
Route of Administration
- Oral Drugs
- Penile Injections
- Topical Drugs
Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Portals
- Devices
Type
- Penile Implants
- Vacuum Construction Devices
- Shock Wave Therapy
- Others
MARKET STRUCTURE
- Market Dynamics
- Competitive Landscape of ED Treatment Market
- Key Vendors
- Other Prominent Vendors
APPENDIX
- Research Methodology
- Abbreviations
- About the Analyst
Table of Contents
Chapter - 1: Ed Treatment Market Overview
Chapter - 2: Ed Treatment Market
Chapter - 3: Ed Treatment Market Segmentation Data
Chapter - 4: Key Regions Overview
Chapter - 5: Ed Treatment Market Prospects & Opportunities
Chapter - 6: Ed Treatment Industry Overview
Chapter - 7: Appendix
List of Tables
Companies Mentioned
- Bayer
- Pfizer
- Coloplast
- Eli Lilly and Company
- Boston Scientific
- Teva Pharma
- Viatris
- Dong-A Socio
- Vivus
- Cristalia
- Dr.Reddy’s
- Aurobindo
- Seelos Therapeutics
- Menarini Group
- GSK plc
- Futura Medical
- Sanofi
- Cipla
- Lupin
- Advanz Pharma
- Sandoz
- IX Biopharma
- Domier Medtech
- Zephyr Surgical Implants
- Augusta Medical Systems
- Metuchen Pharmaceuticals
- SK Chemicals
- Endo International
- Ferring Pharmaceuticals
- Alembic Pharmaceuticals
- Guangzhou Pharmaceuticals
- Launch Medical
- Bonro Medical
- Owen Mumford
- Direx Group
- Zimmer Medizin Systems
- MTS Medical UG
- Medispec
- Inceler Medical
- NOVAmedtek
- Wikkon
- Top Quality Group
- Promedon
- Timm Medical Technologies
- Global Life Technologies
- Urology Health Store
- Hims
Methodology
Our research comprises a mix of primary and secondary research. The secondary research sources that are typically referred to include, but are not limited to, company websites, annual reports, financial reports, company pipeline charts, broker reports, investor presentations and SEC filings, journals and conferences, internal proprietary databases, news articles, press releases, and webcasts specific to the companies operating in any given market.
Primary research involves email interactions with the industry participants across major geographies. The participants who typically take part in such a process include, but are not limited to, CEOs, VPs, business development managers, market intelligence managers, and national sales managers. We primarily rely on internal research work and internal databases that we have populated over the years. We cross-verify our secondary research findings with the primary respondents participating in the study.
LOADING...
